title: Visual outcomes of pars plana vitrectomy with epiretinal membrane peel in patients with uveitis.
abstract: OBJECTIVE
  To report the outcomes of pars plana vitrectomy with epiretinal membrane (ERM) peel, with or without internal limiting membrane peel, in patients with uveitis.
  
  
  METHODS
  Retrospective interventional case series of patients undergoing pars plana vitrectomy with ERM peel between January 2005 and March 2012. Sixteen consecutive patients (16 eyes) were identified, with a minimum postoperative follow-up of 6 months. Visual acuity, anatomical outcomes, perioperative control of inflammation, and complications were assessed.
  
  
  RESULTS
  The mean age at surgery was 47.3 years (range, 14-68 years), with a mean duration of ERM at surgery of 21.3 months (3-84 months). At 6 months, visual acuity improved in 31.25% of eyes, stabilized in 31.25%, and was worse in 37.5%. The causes of reduced visual acuity postoperatively included severe preexisting macular pathology and unoperated cataract.
  
  
  CONCLUSIONS
  Pars plana vitrectomy with ERM peel in eyes with uveitis may improve or stabilize visual acuity, especially in eyes with macular traction, but in the absence of traction, outcomes are variable and unpredictable. Prevention of ERM formation by aggressive control of inflammation is important.
authors.affiliation: The University of Manchester, Manchester Academic Health Science Center, Manchester Royal Eye Hospital, Central Manchester Foundation Trust, Manchester, United Kingdom.
authors.forename: Rajeev G
authors.initials: RG
authors.lastname: Tanawade
authors.forename: Loukia
authors.initials: L
authors.lastname: Tsierkezou
authors.forename: Mandeep S
authors.initials: MS
authors.lastname: Bindra
authors.forename: Niall A
authors.initials: NA
authors.lastname: Patton
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Jones
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D058450:Endotamponade; D019773:Epiretinal Membrane / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D014792:Visual Acuity / Q000502:physiology*; D014821:Vitrectomy; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011239:Prednisolone; D009173:Mycophenolic Acid; D001379:Azathioprine